Trial Profile
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Diabetes insipidus
- Focus Therapeutic Use
- 07 Oct 2021 Planned End Date changed from 28 Feb 2020 to 31 Jan 2024.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.
- 30 May 2016 New trial record